Switching from natalizumab to antiCD20 monoclonal antibodies : Short transition interval is associated with improved outcome
Recent Publication
In the treatment of relapsing-remitting multiple sclerosis, patients often switch from natalizumab to so-called anti-CD20 antibodies. An international study involving St. Pölten University Hospital has investigated how the length of the transition period affects the success of treatment. The result: if the new therapy is started within 30 days, the disease usually remains stable - longer breaks, on the other hand, increase the risk of new relapses. The changeover also proved to be safe, with only a few serious infections.
Bsteh, G., Hoepner, R., Gernert, J. A., Berek, K., Gradl, C., Kliushnikova, D., Damulina, A., Traxler, G., Föttinger, F., Habernig, S., Krajnc, N., Betancourt, A. X. L., Ponleitner, M., Zrzavy, T., Deisenhammer, F., Di Pauli, F., Havla, J., Khalil, M., Kümpfel, T., ... Hegen, H. (2025). Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcome. European Journal of Neurology, 32(1), e16587. Article e16587. https://doi.org/10.1111/ene.16587
OÄ Dr. Christiane Gradl
Division of Neurology (University Hospital St. Pölten)